Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11684508 | 0.92 | MEN1 (0.74) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL11684541 | 0.92 | MEN1 (0.74) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL11685544 | 0.91 | MEN1 (0.73) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL11685219 | 0.91 | MEN1 (0.73) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL89815 | 0.85 | MEN1 (0.54) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL90448 | 0.85 | MEN1 (0.57) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL23124935 | 0.85 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL13262991 | 0.85 | KDM1A (0.60) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL19650826 | 0.85 | KMT2A (0.57) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL20847771 | 0.84 | NPC1 (0.65) | MEN1KMT2AALDH1A1KDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004105738-A2 | USE OF TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105762-A1 | MEDICAL USE OF DIAZABICYCLONONENE DERIVATIVES AS INHIBITORS OF PARASITE ASPARTIC PROTEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-6143917-A | FROM A DIARYL CARBONATE AND AN AMINE COMPOUND HAVING AT LEAST ONE HYDROGEN ATOM LOCATED AT AN N-POSITION UNDER MODERATE CONDITIONS AT A HIGH REACTION RATE WITH A HIGH SELECTIVITY AND WITH A HIGH YIELD | UBE INDUSTRIES, LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0902014-A1 | PROCESS FOR PRODUCING ARYL CARBAMATES | UBE INDUSTRIES LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | MEN1 1386/4885KMT2A 4717/4885ALDH1A1 1307/4885 |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | MEN1 2389/4885KMT2A 4221/4885ALDH1A1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.